Alzheimer's disease (AD) is characterized by two major pathological lesions in the brain,
amyloid plaques and neurofibrillary tangles (NFTs) composed mainly of amyloid-β (Aβ) …

Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer's disease
and related human tauopathies. There is a growing body of evidence indicating that …

Compelling experimental evidence suggests that microglial activation is involved in the
spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology …

Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging
systems. Using the topographical information from [18F] MK6240 tau positron-emission …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Braak stages of tau neurofibrillary tangle accumulation have been incorporated in the
criteria for the neuropathological diagnosis of Alzheimer's disease. It is expected that Braak …

A panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau
pathologies in Alzheimer's disease (AD), although sensitive detection of frontotemporal …

Animal studies suggest that the apolipoprotein E ε4 (APOE ε4) allele is a culprit of early
microglial activation in Alzheimer's disease (AD). Here, we tested the association between …